ACE1-I/D Polymorphism in Patients With Severe COVID-19

Authors

Fouzieh Karimi1,*, Vahedeh Hosseini2, Abbas Ahmadi2, Fahimeh Ranjbar Kermani1, Shirin Ferdowsi1
1Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
2Cellular and Molecular Research Center, Research Institute for health development & Department of Molecular Medicine and Genetics, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran.
*Corresponding Author: Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran Email: [email protected]

Journal of Cellular & Molecular Anesthesia:Vol. 8, issue 3; e149285
Published online:Feb 28, 2023
Article type:Research Article
How to Cite:Karimi F, Hosseini V, Ahmadi A, Kermani FR, Ferdowsi S. ACE1-I/D Polymorphism in Patients With Severe COVID-19. J Cell Mol Anesth. 2023;8(3):e149285. doi: https://doi.org/10.22037/jcma.v8i3.40994

Abstract

Background: In several studies, insertion/deletion (I/D) polymorphism in the angiotensin-converting enzyme 1 (ACE1) gene is described as a genetic risk factor for coronavirus disease 2019 (COVID-19) infection. However, in some studies, this contribution is not confirmed. Therefore, this study aimed to evaluate the genotypic and allelic frequency of ACE1-D/I in Kurdish patients with severe COVID-19 in Iran. Methods: A total of 95 patients with PCR positive-COVID-19 were enrolled in this cross-sectional study. Genomic DNA was extracted from peripheral blood leucocytes using the salting out method. All cases were genotyped for ACE1-I/D polymorphism using polymerase chain reaction (PCR). Death percentage from COVID-19 after two months? follow-up was analyzed.?Results: Of?the 95 patients, 48 were female (50.5%) and 47 were male (49.5%) with a mean age of 61.9?18.7 years. The ID genotype was the most prevalent (52.6%) followed by DD (32.6%) and II (14.7%). The D and I allele frequencies were 58.9%, and 41.1%, respectively. The D allele frequency was higher in patients with SpO2?90% (P = 0.048). The mortality percentage was 18.9% (8 females and 10 males). The frequency of the DD, ID, and II genotypes in patients who died from COVID-19 was 27.7%, 61,1%, and 11.1%. Conclusions: Our results indicated that the ACE1- D allele can be a genetic risk factor in COVID-19 patients. Further studies on different ethnicities and geographical regions are needed to evaluate this polymorphism in COVID-19 infection.

Highlights

Copyright

© 2023, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Similar Articles

31
Oct
2024
A Multicentric Study of ACE2 rs2285666 Polymorphism: The Association with COVID-19 in the Iranian Population

A Multicentric Study of ACE2 rs2285666 Polymorphism: The Association with COVID-19 in the Iranian Population

Hadi Razavi Nikoo,
Seyed Majid Fatahi,
Mahdieh Taheri,
Mohammad Jamshidi,
Ali Safarzadeh,
Ashkan Alamdary
,et al.

Razavi Nikoo H, Fatahi SM, Taheri M, Jamshidi M, Safarzadeh A, et al. A Multicentric Study of ACE2 rs2285666 Polymorphism: The Association with COVID-19 in the Iranian Population. Jundishapur J Microbiol. 2024;17(10):e153765. doi: https://doi.org/10.5812/jjm-153765

19
Oct
2021

Effect Of Angiotensin-Converting Enzyme Inhibitors And Angiotensin Receptor Blockers On the Clinical Outcome In COVID-19 Patients With Hypertension

Zahra Fakhrae,
Saeid Bitaraf,
Roohangize Nashibi,
Fatemeh Ahmadi,
Safoura Khosravi,
Shokrollah Salmanzadeh

Fakhrae Z, Bitaraf S, Nashibi R, Ahmadi F, Khosravi S, et al. Effect Of Angiotensin-Converting Enzyme Inhibitors And Angiotensin Receptor Blockers On the Clinical Outcome In COVID-19 Patients With Hypertension. J Cell Mol Anesth. 2021;6(4):e149739. doi: https://doi.org/10.22037/jcma.v6i4.35596

19
Sep
2022
ACE2 in SARS-CoV-2-Mediated COVID-19: A Brief Review

ACE2 in SARS-CoV-2-Mediated COVID-19: A Brief Review

Pooria Safarzadeh Kozani,
Setareh Dashti Shokoohi,
Narges Baharifar,
Sepideh Sheikhi,
Fatemeh Khalaf Shamsabadi,
Forough Chamaie Nejad
,et al.

Safarzadeh Kozani P, Dashti Shokoohi S, Baharifar N, Sheikhi S, Khalaf Shamsabadi F, et al. ACE2 in SARS-CoV-2-Mediated COVID-19: A Brief Review. J Adv Immunopharmacol. 2022;2(4):e130682. doi: https://doi.org/10.5812/tms-130682

24
Aug
2024
Biochemical Risk Factors of Atherosclerosis in Patients with Severe and Non-severe COVID-19

Biochemical Risk Factors of Atherosclerosis in Patients with Severe and Non-severe COVID-19

Maryam Shahali,
Ashkan Alamdary,
Alireaza Gholami,
Rasul Moukhah,
Seyed Dawood Mousavi-Nasab,
Mohammad Javad Hossein Tehrani
,et al.

Shahali M, Alamdary A, Gholami A, Moukhah R, Mousavi-Nasab SD, et al. Biochemical Risk Factors of Atherosclerosis in Patients with Severe and Non-severe COVID-19. Arch Clin Infect Dis. 2024;19(4):e144661. doi: https://doi.org/10.5812/archcid-144661

20
Apr
2022
Evaluation of Mutation in Spike Gene of Covid-19 in Iranian Patients

Evaluation of Mutation in Spike Gene of Covid-19 in Iranian Patients

Mohammad Gholami,
Negin Hosseini Rouzbahani,
Hamed Naghoosi,
Sajad Fani-Kheshti,
Seyyed-Javad Hosseini-Shokouh

Gholami M, Hosseini Rouzbahani N, Naghoosi H, Fani-Kheshti S, Hosseini-Shokouh S. Evaluation of Mutation in Spike Gene of Covid-19 in Iranian Patients. Ann Mil Health Sci Res. 2022;20(1):e123942. doi: https://doi.org/10.5812/amh-123942

More by these authors

Fouzieh KarimiPubMedScholar
Vahedeh HosseiniPubMedScholar
Abbas AhmadiPubMedScholar
Fahimeh Ranjbar KermaniPubMedScholar
Shirin FerdowsiPubMedScholar
Share
Cited by
Metrics
Indexed in